Meta-Analysis of Subcutaneous vs. Intravenous PD-1/PD-L1 Inhibitors for Solid Tumors

A systematic review and meta-analysis of three randomized controlled trials with 1,243 patients compares subcutaneous and intravenous administration of PD-1/PD-L1 inhibitors. The analysis, authored by Peiye Wu and last updated in April 2026, found no significant differences in overall survival, progression-free survival, or objective response rate between the two administration routes. The document synthesizes evidence on pharmacokinetics, efficacy, and safety outcomes for these cancer immunotherapies.

Use Cases

• Compare efficacy metrics like overall survival and progression-free survival between subcutaneous and intravenous administration routes.
• Analyze safety profiles and adverse event incidence, such as arthralgia and injection site reactions, for different drug delivery methods.
• Review pharmacokinetic data on serum drug concentrations for PD-1/PD-L1 inhibitors.
• Support literature reviews on the development history and future prospects of subcutaneous immunotherapy administration.

Strengths

• Analysis is based on three randomized controlled trials, a study design that suggests a structured evidence base.
• Includes data from 1,243 total patients, with 746 in the subcutaneous group and 497 in the intravenous group.
• Reports specific statistical outcomes, such as hazard ratios and confidence intervals for key efficacy endpoints.
• Has a registered systematic review protocol (CRD420251161810), which indicates a predefined methodology.

Limitations

• The dataset is a 683.6 KB DOCX document; the underlying tabular data or full study records are not directly accessible as structured data.
• Row count for any underlying data tables is unknown, which may limit suitability assessment for computational analysis.
• Column-level documentation for any potential tables is absent; field semantics must be inferred from the document text.

Provenance

Source

figshare

Collection Method

Systematic review and meta-analysis of studies from PubMed, Embase, and The Cochrane Library up to October 10, 2025.

Time Range

Studies from database inception to October 2025.

Freshness

Last updated 2026-04-27 04:11:19; freshness should be verified.